SCHEMBL3765124

SCHEMBL3765124

COc1cccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.59
MAPT P10636 4/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ADAMTS5 Q9UNA0 1/20 0.52
GFER P55789 2/20 0.52
LMNA P02545 1/20 0.51
DRD4 P21917 1/20 0.51
KDM4E B2RXH2 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM2B Q8NHM5 1/20 0.50
LDHA P00338 1/20 0.50
CCR1 P32246 1/20 0.49
ADAMTS4 O75173 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773498 0.98 TSHR (0.56) TSHRMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3777440 0.97 TSHR (0.55) TSHRMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3773249 0.90 KDM2B (0.51) TSHRMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3763175 0.88 GAA (0.60) TSHRMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3771355 0.87 MEN1 (0.56) TSHRMAPTALDH1A1MEN1KMT2A
SCHEMBL3776429 0.86 GAA (0.61) ALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL3776961 0.86 ALDH1A1 (0.63) TSHRALDH1A1MEN1KMT2ALMNA
SCHEMBL3770061 0.86 SIGMAR1 (0.63) TSHRMAPTALDH1A1MEN1KMT2A
SCHEMBL3762993 0.86 ALDH1A1 (0.60) TSHRMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3771719 0.86 MEN1 (0.74) TSHRMAPTALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TSHR 436/4885MAPT 1475/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.